ЗАБОЛЕВАНИЕ СПЕКТРА ОПТИКОНЕЙРОМИЕЛИТА: ДИАГНОСТИКА И ЛЕЧЕНИЕ, ОПЫТ КЛИНИЧЕСКИХ НАБЛЮДЕНИЙ

Заболевание спектра оптиконейромиелита (СОНМ) – совокупность расстройств центральной нервной системы воспалительной и, наиболее вероятно, аутоиммунной природы, с рецидивирующим, инвалидизирующим течением и преимущественным поражением зрительных нервов, спинного мозга и ствола головного мозга. Выделены два варианта заболевания СОНМ: серопозитивный по антителам к аквапорину-4 (AQP4-IgG) и серонегативный, который отмечается в 25 % случаев. Приведены современные представления о данной патологии, представлен собственный опыт клинических наблюдений пациентов. 

1. Wingerchuk D, Lennon V, Lucchinetti C, Pittock S, Weinshenker B. The spectrum of neuromyelitis optica. The Lancet Neurology. 2007;6(9):805-815.

2. Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. Journal of Neurology. 2012;260(1):100-104.

3. Wingerchuk D, Lennon V, Pittock S, Lucchinetti C, Weinshenker B. Revised diagnostic criteria for neuromyelitis optica. American Journal of Ophthalmology. 2006;142(4):715-716.

4. Lennon V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. The Lancet. 2004;364(9451):2106-2112.

5. Baba T, Nakashima I, Kanbayashi T, Konno M, Takahashi T, Fujihara K et al. Narcolepsy as an initial manifestation of neuromyelitis optica with antiaquaporin-4 antibody. Journal of Neurology. 2009;256(2):287-288.

6. Kim W, Kim S, Hyun Lee S, Feng Li X, Jin Kim H. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal. 2011;17(9):1107-1112.

7. Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.

8. Oh J, Levy M. Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. Neurology Research International. 2012;2012:1-13.

9. Asgari N, Lillevang S, Skejoe H, Falah M, Stenager E, Kyvik K. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76(18):1589-1595.

10. Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of Neuromyelitis Optica in the World: A Systematic Review and Meta-Analysis. Multiple Sclerosis International. 2015;2015:1-8.

11. Quek A, McKeon A, Lennon V, Mandrekar J, Iorio R, Jiao Y et al. Effects of Age and Sex on Aquaporin-4 Autoimmunity (S60.002). Neurology. 2012;78(Meeting Abstracts 1):S60.002-S60.002.

12. Flanagan E, Cabre P, Weinshenker B, Sauver J, Jacobson D, Majed M et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Annals of Neurology. 2016;79(5):775-783.

13. Matiello M, Kim H, Kim W, Brum D, Barreira A, Kingsbury D et al. Familial neuromyelitis optica. Neurology. 2010;75(4):310-315.

14. Guimaraães Brum D, Barreira A, dos Santos A, Kaimen-Maciel D, Matiello M, Costa R et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Multiple Sclerosis Journal. 2009;16(1):21-29.

15. Iyer A, Elsone L, Appleton R, Jacob A. A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity. 2014;47(3):154-161.

16. Figueroa M, Guo Y, Tselis A, Pittock S, Lennon V, Lucchinetti C et al. Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Metastatic Carcinoid Expressing Aquaporin-4. JAMA Neurology. 2014;71(4):495.

17. Nagelhus E, Ottersen O. Physiological Roles of Aquaporin-4 in Brain. Physiological Reviews. 2013;93(4):1543-1562.

18. Ikeshima-Kataoka H. Neuroimmunological Implications of AQP4 in Astrocytes. International Journal of Molecular Sciences. 2016;17(12):1306.

19. Saadoun S, Papadopoulos M. Role of membrane complement regulators in neuromyelitis optica. Multiple Sclerosis Journal. 2015;21(13):1644-1654.

20. Duvernoy H, Risold P. The circumventricular organs: An atlas of comparative anatomy and vascularization. Brain Research Reviews. 2007;56(1):119-147.

21. Bartanusz V, Jezova D, Alajajian B, Digicaylioglu M. The blood-spinal cord barrier: Morphology and Clinical Implications. Annals of Neurology. 2011;70(2):194-206.

22. Saadoun S, Waters P, Bell B, Vincent A, Verkman A, Papadopoulos M. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133(2):349-361.

23. Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain. 2010;133(9):2578-2591.

24. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology. 2010;75(3):208-216.

25. Patterson S, Goglin S. Neuromyelitis Optica. Rheumatic Disease Clinics of North America. 2017;43(4):579-591.

26. Rosales D, Kister I. Common and Rare Manifestations of Neuromyelitis Optica Spectrum Disorder. Current Allergy and Asthma Reports. 2016;16(6).

27. Nakajima H, Fujiki Y, Ito T, Kitaoka H, Takahashi T. Anti-Aquaporin-4 Antibody-Positive Neuromyelitis Optica Presenting with Syndrome of Inappropriate Antidiuretic Hormone Secretion as an Initial Manifestation. Case Reports in Neurology. 2011;3(3):263-267.

28. Poppe A, Lapierre Y, Melançon D, Lowden D, Wardell L, Fullerton L et al. Neuromyelitis optica with hypothalamic involvement. Multiple Sclerosis Journal. 2005;11(5):617-621.

29. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131(11):3072-3080.

30. Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology. 2009;72(22):1960-1961.

31. Kim W, Lee J, Li X, Kim S, Han B, Lee B et al. Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Multiple Sclerosis Journal. 2011;18(5):578-586.

32. Mealy M, Wingerchuk D, Greenberg B, Levy M. Epidemiology of Neuromyelitis Optica in the United States. Archives of Neurology. 2012;69(9).

33. Weinshenker B, Wingerchuk D. Neuromyelitis Spectrum Disorders. Mayo Clinic Proceedings. 2017;92(4):663-679.

34. Kezuka T, Tanaka K, Matsunaga Y, Sato D, Takahashi T, Waters P et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;83(5):475-476.

35. Kitley J, Woodhall M, Waters P, Leite M, Devenney E, Craig J et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79(12):1273-1277.

36. Zamvil S, Slavin A. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurology - Neuroimmunology Neuroinflammation. 2015;2(1):e62.

37. Flanagan E, Weinshenker B. Neuromyelitis Optica Spectrum Disorders. Current Neurology and Neuroscience Reports. 2014;14(9).

38. Tradtrantip L, Zhang H, Saadoun S, Phuan P, Lam C, Papadopoulos M et al. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Annals of Neurology. 2012;71(3):314-322.